Belgian biotech company Rewind Therapeutics picks up Series A funding
Rewind Therapeutics, a Belgian biotech company, has closed 15.2 million euros in Series A financing. The backers were Boehringer Ingelheim Venture Fund, Merck Ventures BV, Participatiemaatschappij Vlaanderen, KU Leuven's Centre for Drug Design and Discovery and KU Leuven Gemma Frisius Fonds.
4 January 2018•1 min read
